JP2024501658A - 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 - Google Patents

多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Download PDF

Info

Publication number
JP2024501658A
JP2024501658A JP2023537923A JP2023537923A JP2024501658A JP 2024501658 A JP2024501658 A JP 2024501658A JP 2023537923 A JP2023537923 A JP 2023537923A JP 2023537923 A JP2023537923 A JP 2023537923A JP 2024501658 A JP2024501658 A JP 2024501658A
Authority
JP
Japan
Prior art keywords
inhibitor
alkyl
flt3
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501658A5 (enExample
Inventor
ホイット，スコット，ブライアン
トーマス，クレイグ，ジョセフ
スターチナウスキー，ダニエル，ティー．
ローゼンバウム，ジャン，スーザン
マルドナド，ガブリエル グラシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children S Hospital Medical Center
Original Assignee
Children S Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children S Hospital Medical Center filed Critical Children S Hospital Medical Center
Publication of JP2024501658A publication Critical patent/JP2024501658A/ja
Publication of JP2024501658A5 publication Critical patent/JP2024501658A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023537923A 2020-12-23 2021-12-23 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Pending JP2024501658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129895P 2020-12-23 2020-12-23
US63/129,895 2020-12-23
PCT/US2021/065037 WO2022140647A1 (en) 2020-12-23 2021-12-23 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024501658A true JP2024501658A (ja) 2024-01-15
JP2024501658A5 JP2024501658A5 (enExample) 2025-01-07

Family

ID=82158501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537923A Pending JP2024501658A (ja) 2020-12-23 2021-12-23 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用

Country Status (9)

Country Link
US (1) US12612410B2 (enExample)
EP (1) EP4267142A4 (enExample)
JP (1) JP2024501658A (enExample)
CN (1) CN117015380A (enExample)
AU (1) AU2021410783A1 (enExample)
CA (1) CA3201841A1 (enExample)
IL (1) IL303887A (enExample)
MX (1) MX2023006938A (enExample)
WO (1) WO2022140647A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP2014508180A (ja) * 2011-03-17 2014-04-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イミダゾピラジン
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
US11542261B2 (en) * 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
DK3500571T3 (da) * 2016-08-17 2021-03-08 Childrens Hospital Med Ct Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
TW201822764A (zh) * 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
WO2019002606A1 (en) * 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP2014508180A (ja) * 2011-03-17 2014-04-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イミダゾピラジン
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinas", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 25, no. 6, JPN6025030386, 2010, pages 844 - 853, ISSN: 0005651854 *

Also Published As

Publication number Publication date
CN117015380A (zh) 2023-11-07
AU2021410783A9 (en) 2024-10-17
IL303887A (en) 2023-08-01
MX2023006938A (es) 2023-10-13
US20240294530A1 (en) 2024-09-05
US12612410B2 (en) 2026-04-28
AU2021410783A1 (en) 2023-08-10
EP4267142A1 (en) 2023-11-01
CA3201841A1 (en) 2022-06-30
WO2022140647A1 (en) 2022-06-30
EP4267142A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
US12534469B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
JP2023538242A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US20250154144A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
TW202415655A (zh) １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑
US12612410B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
US20250368648A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023150601A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
JP2025525325A (ja) キノロンｂｃｌ６二官能性分解剤
JP2026506363A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
EP4598539A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023250431A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途
WO2025137567A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324